Based on the Qiagen NV stock forecast from 7 analysts, the average analyst target price for Qiagen NV is USD 54.88 over the next 12 months. Qiagen NV’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Qiagen NV is Slightly Bearish, which is based on 7 positive signals and 9 negative signals. At the last closing, Qiagen NV’s stock price was USD 42.33. Qiagen NV’s stock price has changed by +0.57% over the past week, +0.50% over the past month and +4.13% over the last year.
No recent analyst target price found for Qiagen NV
No recent average analyst rating found for Qiagen NV
Company Overview Qiagen NV
Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, such as STR assays for human ID, and assays for food contamination; PCR instruments include digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It also offers predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a collaboration with the U.S. FBI; and with Bio-Manguinhos/Fiocruz to detect malaria and dengue. The company was founded in 1984 and is headquartered in Venlo, the Netherlands. Read Less
Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping...Read More
Frequently Asked Questions About Qiagen NV (QGEN) Stock
Based on ratings from 7 analysts Qiagen NV's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 6 buy, sell and 2 hold ratings.
QGEN stock's dividend yield is 2.94%.
Our analysis grades QGEN stock's dividend yield at A+. This means that QGEN stock's dividend yield is above 100% of the stocks in the Diagnostics & Research sector in the NYE exchange.
Based on this QGEN may be a good dividend stock for its sector.
Based on targets from 7 analysts, the average taret price for QGEN is USD 54.88 over the next 12 months. The maximum analyst target price is USD 75 while the minimum anlayst target price is USD 45.
QGEN stock's Price/Earning ratio is 126.71.
Our analysis grades QGEN stock's Price / Earning ratio at F. This means that QGEN stock's Price/Earning ratio is above 75% of the stocks in the Diagnostics & Research sector in the NYE exchange.
Based on this QGEN may be a overvalued for its sector.
The last closing price of QGEN's stock was USD 42.33.
The most recent market capitalization for QGEN is USD 9.57B.
Based on targets from 7 analysts, the average taret price for QGEN is projected at USD 54.88 over the next 12 months.
This means that QGEN's stock price may go up by +29.64% over the next 12 months.
We can't find any ETFs which contains Qiagen NV's stock.
As per our most recent records Qiagen NV has 5,900 Employees.
Qiagen NV's registered address is Hulsterweg 82, Venlo, Netherlands, 5912 PL.
You can get more information about it from Qiagen NV's website at https://www.qiagen.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Qiagen NV (QGEN) Stock
Based on ratings from 7 analysts Qiagen NV's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 6 buy, sell and 2 hold ratings.
QGEN stock's dividend yield is 2.94%.
Our analysis grades QGEN stock's dividend yield at A+. This means that QGEN stock's dividend yield is above 100% of the stocks in the Diagnostics & Research sector in the NYE exchange.
Based on this QGEN may be a good dividend stock for its sector.
Based on targets from 7 analysts, the average taret price for QGEN is USD 54.88 over the next 12 months. The maximum analyst target price is USD 75 while the minimum anlayst target price is USD 45.
QGEN stock's Price/Earning ratio is 126.71.
Our analysis grades QGEN stock's Price / Earning ratio at F. This means that QGEN stock's Price/Earning ratio is above 75% of the stocks in the Diagnostics & Research sector in the NYE exchange.
Based on this QGEN may be a overvalued for its sector.
The last closing price of QGEN's stock was USD 42.33.
The most recent market capitalization for QGEN is USD 9.57B.
Based on targets from 7 analysts, the average taret price for QGEN is projected at USD 54.88 over the next 12 months.
This means that QGEN's stock price may go up by +29.64% over the next 12 months.
We can't find any ETFs which contains Qiagen NV's stock.
As per our most recent records Qiagen NV has 5,900 Employees.
Qiagen NV's registered address is Hulsterweg 82, Venlo, Netherlands, 5912 PL.
You can get more information about it from Qiagen NV's website at https://www.qiagen.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for QGEN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
